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Bile acids (BAs) are amphipathic molecules synthesized from
cholesterol in the liver. They are physiological detergents that play
important roles in facilitating hepatobiliary secretion of endobiotic
and xenobiotic metabolites. In the intestines, BAs help intestinal
absorption of dietary fats, fat-soluble vitamins, and other nutri-
tions1. Over the past decade, BAs change beyond digestive
surfactants to signaling molecules in a wide range of biological
functions, including glucose and lipid metabolism, energy home-
ostasis, and the modulation of immune response1–3. The regulatory
functions of BAs are mainly the result of activation of intracellular
ligand-activated nuclear receptors (NRs), such as the farnesoid X
receptor (FXR, NR1H4)4–6 and cell surface G protein-coupled
receptors (GPCRs), speciﬁcally the G protein-coupled BA receptor
(TGR5 or GPBAR-1)7,8. Chenodeoxycholic acid (CDCA) is the
most potent BA for FXR9–11. In contrast, lithocholic acid (LCA)
and taurolithocholic acid (TLCA) are most potent endogenous
ligands for TGR5 with an EC50 of 600 and 300 nmol/L,
respectively12–14. FXR has been considered as a master regulator
of BA synthesis and secretion, lipid and glucose metabolism in the
liver and intestine15,16. In contrast, activation of TGR5 by BAs
stimulated adenylate cyclase, rapid intracellular cAMP production,
and protein kinase A activation. Such regulatory function of TGR5
plays important roles in regulating energy metabolism in brown
adipose tissue, relaxing and reﬁlling gallbladder, secreting
glucagon-like peptide 1 (GLP-1) in intestinal endocrine cells and
controlling gastrointestinal motility to help maintain BA, lipid and
glucose homeostasis2,17.
Abnormal BA metabolism has been associated with liver injury,
metabolic disorders, cardiovascular diseases and digestive system
diseases such as inﬂammation bowel disease (IBD) and colorectal
cancer18–21. FXR has been suggested to counteract pro-
inﬂammatory and pro-atherogenic responses in cardiovascular
diseases22. Moreover, FXR plays a pivotal role in regulating liver
inﬂammation and regeneration as well as in regulating the extent
of inﬂammatory responses, barrier function and prevention of
bacterial translocation in the intestinal tract23–25. Direct modulation
of BA receptor activities by synthetic and natural FXR agonists or
antagonists has shown promise in treating human diseases related to
metabolic perturbations and inﬂammation23,26–29. Here, we will
focus on the current understanding of the functions of BAs and FXR
in enterohepatic circulation, with special emphasis on their roles in
pathophysiology of the gastrointestinal tract.2. Bile acid nuclear receptor FXR
FXR belongs to a subclass of metabolic receptors within the
NR-family and is identiﬁed as an NR for BAs4–6. It is expressed
in several tissues, including liver, intestine, adipose tissue, the
vascular wall, pancreas and kidney30. Four FXR splice variants
have been identiﬁed, i.e. FXRα1–4. These isoforms showdifference in spatial and temporal expression patterns as well as
in transcriptional activities31. The general structure of FXR
consists of an N-terminal DNA binding domain (DBD), a unique
ligand binding domain (LBD) allowing receptor dimerization, and
a C-terminal activation domain (AF2) for co-regulator interac-
tions32. FXR binds to an FXR response element (FXRE) as a
heterodimer with RXR or as monomer to regulate gene expres-
sion32. A large number of publications have shown that FXR
regulates a network of genes in hepatic BA synthesis, biliary BA
secretion, intestinal BA absorption, and hepatic BA uptake,
thereby playing a key role in the regulation of BA homeosta-
sis33–35.
BAs were identiﬁed as endogenous FXR ligands with high
afﬁnity. FXR can be activated by both free and conjugated BAs.
The hydrophobic CDCA is the most efﬁcacious ligand of FXR
(EC50¼approximately 10 mmol/L). The order of potency of BAs
is CDCA4LCA¼deoxycholic acid (DCA)4cholic acid (CA),
whereas hydrophilic BAs, such as ursodeoxycholic acid (UDCA)
and muricholicacid (MCA), cannot activate FXR36. These studies
have suggested for the ﬁrst time that BAs are also endocrine
hormones16,32,37. A number of compounds unrelated to BAs were
also found to act as FXR ligands with varying degrees of afﬁnity,
including androsterone38 and the exogenous natural products such
as forskolin39, epigallocatechin-3-gallate40 and cafestol41. In addi-
tion, a series of synthetic BA derivatives have been developed as
FXR ligands, such as 6α-ethylchenodeoxycholic acid
(6-ECDCA) and bile alcohols, showing a higher afﬁnity with
FXR than the original BAs42. Along with the regulation of BA
metabolism, accumulated data have demonstrated that FXR is a
multipurpose NR that plays an essential role in maintaining lipid
and glucose homeostasis32,37,43. Thus, activation or repression of
FXR can have signiﬁcant inﬂuences on metabolic homeostasis.
FXR ligands have been proposed for potential treatment of
cholestasis44, liver ﬁbrosis27, inﬂammatory bowel disease23, ather-
osclerosis45 and erectile dysfunction46. Detailed analysis of the
ChIP-seq data indicates that the global binding patterns of FXR in
primary human hepatocytes are similar to those in mouse livers.
Therefore, in a major extent, mouse model is suitable for studying
human FXR functions47. Since numerous excellent review articles
on FXR are already available, we will focus on the roles of FXR in
digestive system diseases and type 2 diabetes (T2D).3. FXR and enterohepatic circulation
FXR plays a key role in regulation of BA levels in enterohepatic
circulation. BAs are synthesized in hepatocytes by cholesterol
7α-hydroxylase (CYP7A1), conjugated with taurine or glycine via
bile acid-CoA synthetase (BACS) and bile acid-CoA amino acid
N-acetyltransferase (BAAT), and secreted through the bile cana-
licular membrane by two ABC transporters (bile salt export pump
(BSEP) and multidrug resistance-associated protein 2 (MRP2))
into the canalicular lumen1,33,37. They are stored in the gallbladder
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function to emulsify dietary lipids and vitamines. In the liver,
BAs bind to FXR, which transcriptionally upregulates a protein
called small heterodimer partner (SHP; NR0B2) to inhibit trans-
activity of hepatic nuclear factor 4α (HNF4α) and liver receptor
homolog-1 (LRH-1; NR5A2) that bind to the BA response element
in the Cypza1 and Cyp8b1 gene promoters48.
Roughly 95% of the BAs re-absorption occurs at the terminal
ileum through the apical sodium-dependent bile salt transporter
(ASBT; SLC10A2)49,50. After transporting inside ileal enterocytes
by ASBT, BAs are reversibly bound by the intestinal bile acid-
binding protein (I-BABP) (also known as fatty acid-binding
protein subclass 6 (FABP6)) expressed in the ileum49,51.
I-BABP has an important role in enterohepatic circulation by
regulating BA trafﬁcking. It shuttles BAs from the apical to
basolateral membrane in the enterocytes52. Finally, organic solute
transporter alpha and beta (OSTα and OSTβ) move bile salts to
blood vessels, in accordance with its location at the basolateral
membrane53. Mechanistic studies reveal that BAs generate a
negative feedback on ASBT expression by FXR-mediated induc-
tion of SHP, which binds to and represses the transcriptional
activities of LRH-1 for the Cyp7a1 gene54. The negative regula-
tion of ASBT expression was observed in mice. But it was not
found in rats due to the absence of an LRH-1 responsive element
within the rat Asbt promoter54. Similar to the effect of FXR
activation in the hepatocytes, activation of intestine FXR by BAs
limits BA uptake and promotes basolateral BA secretion to
decrease intracellular BA concentrations. BAs in the enterocytes
bind FXR and increase the expression of IBABP and two
transporters, OSTα and OSTβ, that are responsible for the
transport of BAs from the intestine to the portal vein55,56. Thus,
FXR controls the entire transport of BAs from the intestinal lumen
to the enterocytes, within the enterocytes and ultimately to the
blood vessel for transportation to the liver.
Interestingly, intestinal FXR activation also generates an endo-
crine feedback regulation. Fibroblast growth factor 19 (FGF19) in
humans, and its mouse homolog FGF15 (sometimes referred to as
FGF15/19) are activated by FXR in the ileum57,58. FGF15/19 is
secreted from the ileum to the bloodstream where it circulates to
the liver and suppresses BA synthesis through binding and
activation of the FGF receptor 4 (FGFR4) complexed with
β-Klotho located on the surface of hepatocytes and other epithelial
cells59,60. These effects were not observed in Shp / mice, thus
suggesting that SHP is required for the suppressive effects of
FGF15/1936. Binding of FGF15/19 to the FGFR4/β-Klotho com-
plex strongly suppresses the expression of CYP7A1 through
MAPK-dependent pathways, speciﬁcally, ERK and JNK path-
ways61. Extracellular signal-regulated kinase (ERK) was markedly
elevated by FGF15 administration to mice and deﬁciency of both
JNK and ERK pathways prevented FGF15-mediated suppression
of CYP7A1 and CYP8B1 expression. However, deﬁciency of
either pathway alone had minimal effect on FGF15-mediated
suppression of these genes61. Therefore, intestinal FXR activated
by BAs downregulates CYP7A1 expression indirectly through the
intestinal FGF15/19 synthesis and secretion. In addition, FGF15/
19 was reported to work as a hormone to facilitate gallbladder
ﬁlling by binding to FGFR3, a receptor that is highly expressed in
the gallbladder62. These studies indicate that FXR-FGF15-19
signaling contributes to the control of intestinal BA levels.
Furthermore, FGF15/19 is also recently reported to activate
hepatic glycogen synthesis through elevating the activities of
glycogen synthase kinase 3 (GSK3)63 and to inhibit hepaticgluconeogenesis by inhibiting the cAMP regulatory element-
binding protein (CREB)–peroxisome proliferators-activated recep-
tor γ coactivator protein-1α (PGC-1α) pathway64.4. FXR and inﬂammatory bowel disease
IBD, which primarily includes ulcerative colitis (UC) and Crohn's
disease (CD), represents a group of chronic disorders characterized
by gastrointestinal tract inﬂammation65. Although many details of
IBD have been explored, the exact pathogenetic mechanisms of
IBD have not been fully elucidated. At present, IBD is generally
believed to result from imbalance of gut microbiota, epithelial
dysfunction, and aberrant mucosal immune response66.
Recently, FXR has been implicated to participate in immune
modulation and barrier function in the intestine. FXR alleviates
inﬂammation and preserves the integrity of the intestinal epithelial
barrier in many ways by regulating the extent of the inﬂammatory
response, maintaining the integrity and function of the intestinal
barrier, and preventing bacterial translocation in the intestinal
tract67.
First, FXR plays an important role in the mucosal immune
response, thereby exerting strong inﬂuence on immunoregula-
tion68. Vavassori et al.69 notice that Fxr / mice display
signiﬁcantly elevated pro-inﬂammatory cytokine mRNA expres-
sion in the colon. In two complementary murine models (intra-
rectal administration of trinitrobenzensulfonic acid (TNBS) and
oral administration of dextrane sodium sulfate (DSS)), concurrent
administration of the potent synthetic FXR ligand 6-ECDCA
represses the expression of various proinﬂammatory cytokines,
chemokines and their receptors in wild type, but not Fxr / mice.
In addition, Raybould et al.73 show that FXR activation by
INT-747 prevents DSS- and TNBS-induced intestinal inﬂamma-
tion, with improvement of colitis symptoms, inhibition of epithe-
lial permeability, and reduced goblet cell loss. Furthermore, FXR
activation inhibits proinﬂammatory cytokine production in vivo in
the mouse colonic mucosa, and ex vivo in different immune cell
populations23. These results provide strong support for the
involvement of FXR in IBD due to counter-regulatory effects on
cells of innate immunity23,69. FXR ligands exert anti-inﬂammatory
activities by antagonizing other signaling pathways, in part
through the interaction with other transcription factors, including
activator protein-1 (AP-1), and signal transducers and activators of
transcription 3 (STAT3)70. Several of the intestinal macrophage
genes inhibited by FXR agonists are established targets for nuclear
factor-kappa B (NF-κB) (tumor necrosis factors α (TNFα),
interleukin 1 (IL-1), IL-6, cyclooxygenase-1, cyclooxygenase-2)
and AP-1, two most important transcriptional regulators of innate
and adaptive immunity in cells71 (Fig. 1).
Second, FXR has been implicated in barrier function by
regulating intestinal antibacterial growth. Gut microbiota play
important roles in pathogen defense, immunity, and nutrient
harvest. Recent evidence suggests that there is a regulatory
relationship between the development of IBD and altered gut
microbiota72–74. It has been demonstrated that BAs and gut
microbiota are closely related to each other. Gut microbiota are
involved in the biotransformation of BAs through deconjugation,
dehydroxylation, and reconjugation of BAs75. BAs have antimi-
crobial activities by damaging the bacterial cell membrane, thus
inhibiting bacterial outgrowth76.
The administration of bile or conjugated BAs to ascitic cirrhotic
rats or obstructive jaundice rats eliminates intestinal bacterial
Figure 1 The roles of FXR in the IBD. FXR activation increases mRNA expression of iNOs, ANG1 and CAR12, which are involved in
antibacterial defense by producing antimicrobial peptides (iNOs and ANG1) or maintaining appropriate intestinal pH (CAR12). This is important
for the homeostasis of intestinal luminal contents and epithelial barrier integrity. Moreover, FXR activation induces the repression of inﬂammatory
genes (IL-1, IL-6 and MCP-1) and promotes antimicrobial actions.
Lili Ding et al.138overgrowth, and decreases bacterial translocation and endotoxe-
mia77,78. Inagaki et al.79 provide an explanation for this protective
effect of BAs by demonstrating that intestinal FXR has a crucial
role in limiting bacterial overgrowth and thus protecting the
intestine from bacterial-induced damage. They show that mice
lacking FXR experience bacterial overgrowth, increase intestinal
permeability and contain large amounts of bacteria in mesenteric
lymph nodes, as well as inﬂammation of the intestinal walls.
However, activation of intestinal FXR by GW4064 leads to the
identiﬁcation of several novel intestinal FXR target genes, includ-
ing those encoding angiogenin, carbonic anhydrase 12 and
inducible nitric oxide synthase, which have been reported to have
antibacterial properties79. The cytokine IL-18 is also induced by
FXR stimulation. IL-18 stimulates resistance to an array of
pathogens, including intracellular and extracellular bacteria and
mycobacteria, and appears to have a protective role during the
early, acute phase of mucosal immune response79,80. These results
are consistent with the idea that FXR is critical for controlling
intestinal bacterial growth, which has signiﬁcant implications for
maintaining a competent barrier, thereby contributing to the
prevention of intestinal inﬂammation.5. FXR and colorectal cancer
Colorectal cancer is considered as the third most common form of
cancer and the second most common cause of cancer-related death
worldwide, leading to an incidence of 1.36 million cases estimated
in 2012 (19.2% of total cancer cases) as attending to incidence and
mortality statistics81. In addition to inherited mutations, lifestyle,
diet and nutritional habits are closely related to the development of
colorectal cancer. Recently, there is increasing evidence that a fat-
rich diet is positively associated with colon cancer incidence82–84.
Consumption of high-fat diet has been correlated with elevated
levels of BAs in the colonic lumen as a consequence of increased
fecal excretion of BAs, which at last promote elevated incidence of
colorectal cancer85,86. In addition, population-based studies have
shown that subjects who consume a western diet display elevated
levels of fecal secondary BAs, mostly DCA and LCA, as do
patients diagnosed with colonic carcinomas87,88. Elevated secondary
BA concentrations have detrimental effects on colonic epithelium
architecture and function through multiple mechanisms, such as DNAoxidative damage, inﬂammation, NF-κB activation and enhanced cell
proliferation89. Therefore, BAs can be considered as tumor-promoting
factors in colorectal cancer development82,90,91.
So far, there is considerable evidence for a role of FXR in
modulating intestinal tumorigenesis. Given the crucial roles of
FXR in maintaining BA concentrations within a physiological
range, thereby preventing BA-induced cytotoxicity, the loss of
FXR would contribute to tumorigenesis of colorectal cancer. De
Gottardi et al.92 ﬁrst suggest that FXR mRNA expression is
decreased in colonic polyps, and even more pronounced, in
colonic adenocarcinoma. These results indicate that FXR expres-
sion levels may positively correlated to the degree of malignancy
of colon cancer and there is a causal link between FXR and colon
carcinogenesis in humans. It is indeed further demonstrated by that
FXR deﬁciency leads to signiﬁcantly increased sizes and numbers
of the tumors in two common murine intestine tumorigenesis
models: APCmin mice and azoxymethane (AOM)-induced colon
cancer93. Modica et al.94 consider that FXR activity is relevant to
the pathogenesis of intestinal cancer. On one hand, when FXR is
absent, there is an upregulation of Wnt signaling via increased
inﬁltrating neutrophils and TNFα production with expansion of the
basal proliferative compartment both in the ileum and in the colon,
and a concomitant reduction in the apical, differentiated apoptosis
competent compartment. This scenario leads to increased tumor
progression and early mortality in mice. On the other hand, when
FXR is activated in the differentiated normal enterocytes and in
colon cancer cells, there is an induction of apoptosis and removal
of genetically altered cells, which may otherwise progress to
complete transformation. Thus, up-regulation of FXR expression
in colon tumors might be useful in the treatment of colon cancer.
Further studies on a larger collection of human frozen colon
carcinomas tissues and human cell lines show that FXR expression
may be linked to the development of colorectal carcinomas and
indicate that altered FXR signaling in neoplastic cells offers novel
pathogenetic, prognostic and, in particular, therapeutic insights and
perspectives95. Bailey et al.96 investigate the regulation of FXR
during the development of human colon cancer. The results
showed that FXR is downregulated very early in human colon
cancer development, which is partly due to DNA methylation of
the FXR promoter and increased V-Kiras2 Kirsten rat sarcoma
viral oncogene homolog (KRAS) signaling. Silencing of FXR
alone is not sufﬁcient to initiate colon cancer development, but
FXR and digestive system diseases 139activation of remnant FXR in healthy tissues may prevent and
inhibit the promotion of colon cancer93,94,97. Restoration of basal
FXR expression through inhibition of DNA methylation or KRAS
signaling, or through activation of residual FXR, might slow or
prevent the progression of colorectal cancer96.6. FXR, obesity and T2D
The global prevalence of diabetes in 2010 was 280 million people
worldwide (around 6.2% of the world's total population), and it
has been predicted that in 2030 the prevalence will reach more
than 7.5% of the world's total population, paralleling the aging and
body mass index (BMI) of the population. Obesity is a leading risk
factor for impaired glucose tolerance and T2D. Overweight and
obesity lead to adverse metabolic effects on blood pressure,
cholesterol levels, triglycerides levels and insulin resistance98.
In recent years, a body of evidence has surfaced indicating that
FXR plays an important role not only in BA but also in lipid and
glucose homeostasis99–101. Speciﬁc targeting of FXR may be an
effective way to treat obesity-induced metabolic diseases.
Studies in mice with FXR gene ablation or administering FXR
agonists provided key information demonstrating a central role of
FXR in lipid homeostasis. Fxr / mice display elevated serum
cholesterol and triglyceride levels and excessive accumulation of
fat in the liver99,100. A more detailed study reveals an increased
hepatic synthesis of apolipoprotein B-containing lipoproteins
(mainly VLDL) and a reduced clearance rate of HDL cholesteryl
esters, both of which have theoretically pro-atherogenic effects in
Fxr / mice98. Activation of FXR by BAs or synthetic agonists
lowers plasma triglyceride levels101,102 by a mechanism that
involves the repression of hepatic transcription factor sterol
regulatory element-binding protein 1c (SREBP-1c) expression
and its lipogenic target genes in mouse primary hepatocytes and
liver103,104. The suppression effect of FXR on SREBP-1c expres-
sion is thought to be mediated by a signaling cascade that involves
SHP104. In addition, activation of FXR facilitates the clearance of
VLDL and chylomicrons via repressing the expression of micro-
somal triglyceride transfer protein and apolipoprotein B103. FXR
activation also results in the induction of peroxisome proliferator-
activated receptor α, which promotes fatty acid β-oxidation105
(Fig. 2). Yet, different FXR isoforms display differential effects.
For example, FXRα2 is more effective in reducing elevated HDL
levels and transrepressing hepatic expression of CYP8B1, which is
the regulator of cholate synthesis. In contrast, FXRα4 is involved
in a switch to regulate the hydrophobicity of the bile salt
pool31.
In addition, FXR activation also directly increases the expres-
sion of apolipoprotein Apo CII and AIV102,106,107, which are
activators of lipoprotein lipase (LPL) activity, and decreases the
expression of both ApoCIII108 and ANGTPL3104, which are LPL
inhibitors. However, FXR appears to suppress apolipoprotein A-I
expression100,109,110, the primary protein constituent of high-
density lipoprotein deﬁning its size and shape. FXR also regulates
the expression of phospholipid transfer protein111 that is respon-
sible for the transfer of phospholipids and cholesterol from low to
high-density lipoprotein and suppresses 3-hydroxy-3-methyl-glu-
taryl-CoA reductase, likely involving sterol regulatory element-
binding protein 2112. Another target of FXR is paraoxonase 1, a
protein produced in the liver with phospholipase A2 activity that
may be important for inactivation of proatherogenic lipids
produced by oxidative modiﬁcation of low-density lipoprotein.FXR mediated repression of paraoxonase 1 involves the induction
of ﬁbroblast growth factor 19, its subsequent binding to the
ﬁbroblast growth factor receptor 4, and activation of the c-Jun
N-terminal kinase pathway113,114. Finally, FXR represses propro-
tein convertase subtilisin/kexin 9115, a protein that promotes the
intracellular degradation of the low-density lipoprotein receptor by
interfering with its recycling to the plasma membrane. Collec-
tively, these ﬁndings support the concept that FXR activation
decreases plasma lipid levels by suppressing hepatic lipogenesis
and lipid secretion and increasing the clearance of lipoproteins
from blood (Fig. 2).
In addition to its pleiotropic effects on lipid metabolism, FXR
plays a critical role in glucose homeostasis. The generation and
phenotypic characterization of Fxr / mice conﬁrm this vital role
in the regulation of lipid metabolism and glucose homeostasis.
Fxr / mice not only display elevated serum levels of free fatty
acids (FFAs), triglycerides and high density lipoprotein cholesterol
(HDL-C)99,100, but also develop signs of insulin resistance as
shown by hyperglycemia, impaired glucose tolerance, and severely
blunted insulin signaling in both liver and muscle28,116. High
glucose concentrations increased FXR O-GlcNAcylation, thereby
enhancing its protein stability and transcriptional activity. The
fasting–refeeding experiments show that FXR undergoes
O-GlcNAcylation in fed conditions, which is accompanied with
increased FXR target gene expression and decreased liver bile acid
content117. Activation of FXR by synthetic agonists or hepatic
overexpression of a constitutively active FXR by adenovirus-
mediated gene transfer reduces blood glucose levels in obese fa/fa
rats, diabetic, leptin deﬁcient, diabetic (db/db) mice and wild type
mice28,118. This decrease in plasma glucose levels in db/db mice
was associated with decreased glucose-6-phosphatase expression,
increased glycogen levels and synthesis in the liver, providing
evidence that activation of FXR lowers plasma glucose levels by
sensitizing to insulin action26,116. Pharmacological treatments with
BAs or GW4064, both in vitro in human hepatoma cell lines and
in vivo in mice, decrease the expression of the gene encoding
phosphoenol pyruvate carboxykinase (Pepck) and other gluconeo-
genic genes such as those encoding glucose-6-phosphatase
(G6Pase) and fructose 1,6-bis-phosphatase119,120. Consistent with
these results, CA treatment for ﬁve days decreased Pepck and
G6Pase mRNA levels in wild-type, but not in Fxr / mice121.
This was associated with a decrease in levels of fasting blood
glucose only in wild-type mice, indicating that FXR negatively
regulates gluconeogenesis121 (Fig. 2). Moreover, in vivo GW4064
treatment reduces PEPCK and G6Pase expression in db/db mice28.
Paradoxically, some studies28,116, but not all122, report that FXR
activation by GW4064 induces PEPCK expression, leading to
an increased glucose output in rodent primary hepatocytes
in vitro116.
Recently, there are independent studies identifying a role for
FXR in the regulation of insulin sensitivity29,104,121. Fxr / mice
are associated with impaired glucose tolerance and insulin
resistance. Moreover, whole-body glucose disposal during a
hyperinsulinemic euglycemic clamp is decreased in Fxr / mice.
Consistent with these observations, insulin signaling is impaired in
peripheral insulin-sensitive tissues, including skeletal muscle and
white adipose tissue29,122. Interestingly, treatment with GW4064
signiﬁcantly improved insulin sensitivity in both db/db28 and
ob/ob29 mice. Similar results are obtained when a constitutively
active FXR is over-expressed in db/db mice28. In contrast, FXR
deﬁciency was also shown to be associated with normal hepatic
insulin sensitivity and signaling121,122. The reason for this
Figure 2 The roles of FXR in regulating lipid and glucose metabolism. On one hand, FXR plays an important role in regulating lipid
metabolism. Activation of FXR by BAs or synthetic agonists lowers plasma triglyceride levels by a mechanism that involves the repression of
hepatic transcription factor SREBP-1c expression and its lipogenic target genes in mouse primary hepatocytes and liver. FXR activation also
increases the expression of apolipoprotein Apo CII and AIV and decreases the expression of both Apo CIII 112 and ANGTPL3 to stimulate LPL
activity. In addition, FXR mediates the repression of paraoxonase 1 to inactivate pro-atherogenic lipids produced by oxidative modiﬁcation of low-
density lipoprotein. Furthermore, FXR activation promotes fatty acid β-oxidation by inducing the expression of PPARα. Finally, activation of FXR
facilitates the clearance of very low-density lipoproteins and chylomicrons via repressing the expression of microsomal triglyceride transfer protein
and apolipoprotein B (Apo B). On the other hand, FXR exerts a critical role in regulating glucose homeostasis. Activation of FXR in βTC6 cells
increases Akt phosphorylation and translocation of the glucose transporter GLUT2 at plasma membrane, increasing the glucose uptake by these
cells. FXR-KLF11 regulated pathway has an essential role in the regulation of insulin transcription and secretion induced by glucose. Furthermore,
FXR-SHP negative regulatory cascade can regulate gluconeogenesis in the liver.
Lili Ding et al.140discrepancy is unclear, but may be linked to different genetic
backgrounds (C57Bl6/J28,121 vs. C75Bl6/N121,122) of the mice and/
or the insulin dose used during the clamp. The molecular
mechanisms behind the insulin-sensitizing effect of FXR remain
poorly deﬁned. Since FXR is not expressed in skeletal muscle, it is
conceivable that FXR deﬁciency alters indirectly insulin signaling
in this tissue. Recent studies indicated that FXR is expressed by
pancreatic β-cells and human islets and regulates the insulin
signaling by genomic and non-genomic effects. Genomic effects
include Krüppel-like factor 11 (KLF11)-mediated stimulation of
insulin gene expression. Non-genomic effects include an Akt-
mediated stimulation of glucose induced relocation of glucose
transporter type 2 (GLUT2) in β-cells. Finally, these effects are
reproduced in vivo in a rodent model of insulin-deﬁcient diabetes
developing in non-obese diabetic (NOD) mice123.
In humans, pharmacological approaches to induce persistent
weight loss and improve glucose level of obesity-induced T2D
have so far shown limited effectiveness. However, bariatric
surgery has become an effective therapeutic option for morbid
obesity, surpassing drug therapies and lifestyle interventions124.
Vertical sleeve gastrectomy (VSG) is a bariatric procedure that
involves the removal of up to 80% of the stomach along the
greater curvature, creating a gastric “sleeve” in continuity with the
esophagus and pylorus125. VSG induces loss of body weight and
fat mass and improves glucose tolerance in humans and in rodent
models126–131. The study of Ryan et al.132 suggests that FXR is
required for the sustained maintenance of weight loss and
improved glycemic control after VSG. Furthermore, by identifying
a model resistant to the effects of bariatric surgery, the authors
were able to identify dissect further a role of the microbiota on the
positive effects of bariatric surgery. However, the speciﬁc mechan-
isms by which FXR contributes to glucose control by VSG are still
unknown. Further investigating the roles of FXR in mediating theanti-obesity and anti-diabetes effect of VSG and other surgeries
will be of great interest.7. Conclusions and future perspectives
Research in BA and FXR signaling during the last 20 years has
unraveled its important role in regulation of BA, lipid, glucose,
and energy metabolism. In this review, we have summarized the
roles of FXR in pathophysiology of the digestive system and the
related diseases, including IBD, colorectal cancer and T2D. Recent
studies have shown that FXR activation by its ligands affects both
immune cells and intestinal epithelium, contributing to intestinal
immunomodulation at various levels, thus providing a rationale to
extend the clinical trials of FXR ligands to patients with IBD. The
critical role of FXR in modulating intestinal tumorigenesis is
probably due to its regulation of BA metabolism and detoxiﬁca-
tion, and its activation may confer protection from BA-induced
tumor promoting activities. Activation of FXR improves obesity-
induced T2D by regulating lipid metabolism and glucose homeo-
stasis. FXR is required for the positive metabolic effect of VSG
surgery. Targeting FXR therefore offers an exciting new perspec-
tive for the treatment of these digestive system diseases. However,
the therapeutic beneﬁts or risks of synthetic FXR ligands require
further consideration in light of differences between mice and
humans. One particular challenge in designing FXR agonists is to
separate the desired therapeutic effects from the unwanted side
effects. The design of organ- or gene-speciﬁc FXR modulators
may improve their speciﬁcity and reduce side effects. A better
understanding of the cellular and physiological signaling of FXR
and its cofactors will help develop more selective modulators and
the development of more efﬁcient therapeutics for digestive system
diseases.
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